FDA rolled out its AI tool, Elsa, on Monday, ahead of schedule. The announcement provides fresh insights into how this tech will enhance efficiency across the agency.
The launch follows a STAT report predicting a Tuesday rollout based on a leaked press release.
Commissioner Marty Makary praised Elsa for its ability to save time and speed up regulatory reviews. In an internal message, he highlighted that the tool will help employees "expedite clinical protocol review and reduce the overall time to complete scientific review." 
Details on Elsa’s functionality could be a game changer for the FDA as they continue to evolve their processes.
Expect more updates on how this AI integration impacts regulatory practices and efficiency moving forward.
